Skip to content

Retinal Ganglion Cell Layer in Patients With Intracerebral Processes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02407886
Enrollment
20
Registered
2015-04-03
Start date
2015-03-31
Completion date
2016-05-31
Last updated
2017-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ganglion Cells

Brief summary

Transsynaptic degeneration of the retinogeniculate pathways is well documented to occur in nonhuman primates when the cerebral lesion occurs even during adulthood. In case of humans, retrograde transsynaptic degeneration of the retinogeniculate pathways has been shown to occur following prenatal or perinatal lesions, but its occurrence after cerebral lesions in adults is considerable rare. It is, however, well established that retrograde transsynaptic degeneration affects other neural systems in humans even when the injury occurs during adulthood. Some histopathological evidence points to the possibility of transsynaptic degeneration of the retinogeniculate pathway in humans even when the lesion occurs in adults, but the clinical significance is unknown.' Purpose: To measure the retinal ganglion cell layer (GCL) in patients with visual field defects due to intracerebral processes. To correlate GCL with the localization and type of intracerebral lesion. To compare the GCL with the retinal nerve fibre layer (RNFL) to investigate, which of the 2 parameters is more sensitive to show retinal layer abnormalities. To correlate GCL with visual field defects and electrophysiological parameters.

Interventions

None listed

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* adult patients with intracerebral lesions within the central visual tract * associated visual field defects * investigations (OCT, ERG) possible

Exclusion criteria

* lesions within the optic nerve without extension in the optic tract * neurological disease * optic disc anomalies: glaucoma, nystagmus, high myopia

Design outcomes

Primary

MeasureTime frame
Ganglion cell thicknessmeasurements will be taken at a minimum of 4 weeks after the inital diagnosis

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026